Disease · EFO_0005422

skin aging

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. skin aging. Diseases, record EFO_0005422. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0005422

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: skin aging; Open Targets
Open Targets ID: EFO_0005422; Open Targets
MeSH: D015595; MeSH
Highest stage of its drugs: Approval, for 4 of its 13 drugs, from EMA Human Drugs and FDA; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Approval	EMA Human Drugs	1	0	0	Drugs and targets
DAXIBOTULINUMTOXINA	CHEMBL3707359		Approval	FDA	1	0	0	Drugs and targets
LETIBOTULINUMTOXINA	CHEMBL3707322		Approval	FDA	1	0	0	Drugs and targets
PRABOTULINUMTOXIN A	CHEMBL4297229		Approval	FDA	1	0	0	Drugs and targets
PRASTERONE	CHEMBL90593	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RETINOL	CHEMBL986	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BEDORADRINE SULFATE	CHEMBL2218893	Small molecule	Phase 2	TTD	1	0	0	Drugs and targets
GINKGO	CHEMBL2108466		Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
CAFFEINE	CHEMBL113	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
RESVERATROL	CHEMBL165	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets10

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SNAP25	Synaptosomal-associated protein 25	4	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor; Synaptosomal nerve-associated protein 25 (SNAP-25) proteolytic enzyme	Approval	https://conductscience.org/library/genes/6616	Drugs and targets
ADORA1	Adenosine receptor	1	Adenosine receptor antagonist	Early phase 1	https://conductscience.org/library/genes/134	Drugs and targets
ADORA2A	Adenosine receptor	1	Adenosine receptor antagonist	Early phase 1	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine receptor	1	Adenosine receptor antagonist	Early phase 1	https://conductscience.org/library/genes/136	Drugs and targets
ADORA3	Adenosine receptor	1	Adenosine receptor antagonist	Early phase 1	https://conductscience.org/library/genes/140	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	1	Beta-2 adrenergic receptor agonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
ESR1	Estrogen receptor	1	Estrogen receptor alpha agonist	Unknown	https://conductscience.org/library/genes/2099	Drugs and targets
RARA	Retinoic acid receptor	1	Retinoic acid receptor agonist	Unknown	https://conductscience.org/library/genes/5914	Drugs and targets
RARB	Retinoic acid receptor	1	Retinoic acid receptor agonist	Unknown	https://conductscience.org/library/genes/5915	Drugs and targets
RARG	Retinoic acid receptor	1	Retinoic acid receptor agonist	Unknown	https://conductscience.org/library/genes/5916	Drugs and targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00974480	Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging	Not applicable	120	2010-12-15	Skin Aging	TRETINOIN	Its record names the disease	ClinicalTrials.gov
NCT00113100	Mechanisms of Skin Repair by Topical Estrogen	Not applicable	152		Skin Wrinkling	ESTRADIOL	Its record names the disease	ClinicalTrials.gov
NCT00248989	Effect of DHEA on Skin Aging in Postmenopausal Women	Phase 3	150		Skin Aging, Quality of Life	PRASTERONE	Its record names the disease	ClinicalTrials.gov
NCT00272610	Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin	Phase 2	50		Skin Aging, Purpura	RETINOL	Its record names the disease	ClinicalTrials.gov
NCT05004909	Effectivity of 1 Finger Tip Unit Compared to 2 Finger Tip Units 0.05% Tretinoin Cream	Not applicable	46		Photoaging	TRETINOIN	Its record names the disease	ClinicalTrials.gov
NCT03772418	Topical Preparation of Pomegranate and Ginkgo Biloba for Anti-aging Activities	Phase 1	30		Skin and Subcutaneous Tissue Disorders	GINKGO	Its record names the disease	ClinicalTrials.gov
NCT05734703	Skin Rejuvenation With Topical Extract and Other Nutraceuticals	Early phase 1	25		Wrinkle, Spot Pigmented, Lines Skin	CAFFEINE, RESVERATROL	Its record names the disease	ClinicalTrials.gov
NCT03730649	Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure	Early phase 1	12		Skin Aging	SULFORAPHANE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36364354	RESULT	1	PubMed
35274096	RESULT	1	PubMed
33169920	RESULT	1	PubMed
22615680	RESULT	1	PubMed
18359622	RESULT	1	PubMed
18794456	DERIVED	1	PubMed
17515510	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0005422

GET https://conductscience.org/api/diseases/v1/EFO_0005422/drugs

API reference For AI assistants